Amarin, Eddingpharm Enter Vascepa Development, Commercialization Agreement for China

Amarin Corp plc ($AMRN) and Eddingpharm announced an exclusive agreement for Eddingpharm to develop and commercialize Vascepa® (icosapent ethyl) in the territories of the Mainland China, the Hong Kong and Macao Special Administrative Regions and Taiwan for uses that are currently commercialized and under development by Amarin in the United States based on the MARINE, ANCHOR and ongoing REDUCE-IT clinical trials of Vascepa.

Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.

The Chinese pharmaceutical market has been growing at an annual rate of approximately 20% during the past ten years and currently is the third largest pharmaceutical market in the world. This trend is expected to continue and enable the territory to surpass Japan as the second largest pharmaceutical market in the world by the end of this decade. The combination of the high prevalence rates of hypertriglyceridemia and large population size suggest that a great number of patients in China would benefit from therapy with Vascepa. To date, there has been no prescription grade pharmaceutical omega-3 product in China, and thus there is a high unmet need for an efficacious and safe product to treat the millions of patients that have related lipid abnormalities.

Vascepa is indicated in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Vascepa also demonstrated favorable effects on triglycerides and a spectrum of other lipid, lipoprotein and inflammatory biomarkers in the Phase 3 ANCHOR clinical trial of adult patients with high triglycerides (≥200 mg/dL and < 500 mg/dL) despite statin therapy. Vascepa is currently being studied in a multinational cardiovascular outcomes study, the REDUCE-IT study, to evaluate its effectiveness in reducing the prevalence of first major cardiovascular events in a high-risk patient population. REDUCE-IT enrollment of an estimated 8,000 patients is expected to be completed in 2015, with a protocol pre-specified interim data analysis of efficacy and safety results at 60% of targeted events anticipated in 2016 by the independent Data Monitoring Committee (DMC). Completion of the REDUCE-IT study, if not stopped earlier based on the interim analysis by the independent DMC, is expected in 2017 with published results expected to be available in 2018. Successful REDUCE-IT trial results would position Vascepa to be the first and only prescription grade omega-3 product approved for augmentation to statin therapy for cardiovascular risk reduction indications, a potentially multi-billion dollar commercial opportunity in the United States alone, and position Vascepa for a similar indication in China for which the opportunity is also large.

"Vascepa has the potential to occupy a leading position in the substantial worldwide market for prescription omega-3 products," commented John F. Thero, President and Chief Executive Officer of Amarin. "Our agreement with Eddingpharm reflects the culmination of a competitive process and represents a significant step toward commercializing Vascepa in a major market outside the United States. We are very pleased to be collaborating with Eddingpharm. We believe that their team is well suited to successfully introduce Vascepa in China. Eddingpharm has established development and regulatory capabilities and an impressive commercial organization that has launched many innovative products in China. Eddingpharm's successful track record of long-term alliances with leading global pharmaceutical companies gives us confidence in Vascepa's success in China. The agreement also validates the Vascepa and REDUCE-IT investment hypothesis and marks our start at licensing the ex-US rights to Vascepa to leading commercialization partners around the world."

"There is a large unmet need for a high-quality, well-studied and differentiated prescription grade omega-3 product in the Chinese market," commented Xin Ni, Founder, Chairman and Chief Executive Officer of Eddingpharm. "We are delighted that Amarin has entrusted Eddingpharm to develop and commercialize Vascepa in Greater China. Vascepa has significant commercial potential in the rapidly growing Chinese market. Together with Amarin, we are committed to bringing this medicine to millions of patients in the region."